Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.81 |
| ▸ | MEN1 | O00255 | 7/20 | 0.81 |
| ▸ | GAA | P10253 | 2/20 | 0.79 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 10/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28967916 | 1.00 | KMT2A (0.81) | KMT2AL3MBTL1MEN1GAAKAT8 | |
| SCHEMBL28476008 | 1.00 | KMT2A (0.81) | KMT2AL3MBTL1MEN1GAAKAT8 | |
| SCHEMBL28967929 | 0.94 | KAT8 (0.78) | KMT2AL3MBTL1MEN1GAAKAT8 | |
| SCHEMBL16788880 | 0.94 | KMT2A (0.82) | KMT2AL3MBTL1MEN1GAAKAT8 | |
| SCHEMBL29010258 | 0.94 | KMT2A (0.82) | KMT2AL3MBTL1MEN1GAAKAT8 | |
| SCHEMBL28967925 | 0.94 | KAT8 (0.78) | KMT2AL3MBTL1MEN1GAAKAT8 | |
| SCHEMBL28473982 | 0.94 | KMT2A (0.82) | KMT2AL3MBTL1MEN1GAAKAT8 | |
| SCHEMBL446478 | 0.90 | KMT2A (0.76) | KMT2AL3MBTL1MEN1GAAKAT8 | |
| SCHEMBL420808 | 0.90 | KMT2A (0.76) | KMT2AL3MBTL1MEN1GAAKAT8 | |
| SCHEMBL13011253 | 0.90 | KMT2A (0.76) | KMT2AL3MBTL1MEN1GAAKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031690-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | HAYASHIBARA CO (JP) | 2022-02-03 | — | — | US | disclosed |
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031690-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | SMN1; SMN2, NGF, NLN | KMT2A 4462/4885L3MBTL1 1667/4885MEN1 4332/4885 |
| US-20120035187-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | SNCA, PSEN1, CDR2 | KMT2A 2624/4885L3MBTL1 1255/4885MEN1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.